Celgene Corp. (CELG)

69.65
NASDAQ : Health Technology
Prev Close 69.98
Day Low/High 68.93 / 70.28
52 Wk Low/High 68.91 / 110.81
Avg Volume 4.98M
Exchange NASDAQ
Shares Outstanding 699.25M
Market Cap 48.93B
EPS 3.80
P/E Ratio 17.76
Div & Yield N.A. (N.A)

Latest News

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

These Beaten-Down Stocks Could Rebound on Earnings

These Beaten-Down Stocks Could Rebound on Earnings

Upcoming results from these names -- and many others -- should reassure investors.

Celgene Rated New Overweight at Cantor

Biotechs: Adding to Radius Health, Flexion

Biotechs: Adding to Radius Health, Flexion

This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

Biotech Stocks Rally on Biogen's Landmark Test

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Celgene Is Turning Up as Bulls Gain Control

Celgene Is Turning Up as Bulls Gain Control

With biotech names getting some attention this morning a quick review looks like a good idea.

Celgene Price Weakness in Rear-View Mirror

Celgene Price Weakness in Rear-View Mirror

Charts suggest Celgene has put in a low for now.

Jim Cramer: A GLUM Index For Gloomy Markets

Jim Cramer: A GLUM Index For Gloomy Markets

Taking the measure of what's keeping the markets in the dumps.

The Long Decline in Celgene Stock Could Finally Be Over

The Long Decline in Celgene Stock Could Finally Be Over

Here's our new strategy for the shares.

Emboldened By Biotech Names

Emboldened By Biotech Names

For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.

A Rash of Biotech News

The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades. A rash of biotech news hitting t...

Who Will Win This Game of 'World of Trade Warcraft,' the U.S. or China?

Who Will Win This Game of 'World of Trade Warcraft,' the U.S. or China?

The Chinese have something to lose here, and will not willingly surrender their position of superiority in trade.

Busy Day on Tap: Look for a Solid Jobs Number

It is good once again to be sitting in for Doug Kass on a Friday here on the Daily Diary. Going to be a busy day as we get the monthly jobs report coming out in just over an hour. Although GDP growth (2.3%) did slow in the first quarter from the 3% ...

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Markets Struggle to Find Direction

Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...

Celgene Showing a Bullish Divergence But Is Still In a Downtrend

Celgene Showing a Bullish Divergence But Is Still In a Downtrend

Let's check the charts.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

3 Promising Biotech Stocks to Buy on Dips

3 Promising Biotech Stocks to Buy on Dips

From ANI Pharmaceuticals to T2 Biosystems, these names look good.

Three Biotech Opportunities

Three Biotech Opportunities

Celgene, ANI and T2 are seeing attractive entry points.

Multiple Creep... and More

Recently I have noticed some of Wall Street's younger analysts engaging in "multiple creep." They seem to be treating a 12 EBITD (cash flow) multiple like a 12 PE (price to earnings) ratio. Whoops! No problem, for example, paying 25x EPS for ....Unt...

Three Stocks That Have My Attention

Three Stocks That Have My Attention

I continue to deploy some of the 'dry powder' into the market after its recent hiccup.